STOCK TITAN
  1. Home
  2. News
  3. AKBA

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.

The 42nd Annual J.P. Morgan Healthcare Conference will take place January 8 – 11, 2024, in San Francisco, CA.

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302019671.html

SOURCE Akebia Therapeutics, Inc.

FAQ

When will the CEO of Akebia Therapeutics, Inc. present at the 42nd Annual J.P. Morgan Healthcare Conference?

John Butler, Chief Executive Officer, will present on Thursday, January 11th, 2024 at 11:15 a.m. PST.

Where will the 42nd Annual J.P. Morgan Healthcare Conference take place?

The conference will take place January 8 – 11, 2024, in San Francisco, CA.

How can the webcast of the presentation be accessed?

The webcast can be accessed through the 'Investors' section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

Stock AKBA logo
Akebia Therapeutics, Inc.

NASDAQ:AKBA

AKBA Rankings

#3598 Ranked by Market Cap
#30 Ranked by Stock Gains
N/A Ranked by Dividends

AKBA Latest News

May 9, 2024
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 2, 2024
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
May 1, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 2, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 27, 2024
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

AKBA Stock Data

253.61M
188.22M
2.47%
26.27%
6.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.